REGN rises 3.8% as Pasatru opens a new rare-disease franchise for Regeneron

Regeneron Pharmaceuticals has added another internally developed medicine to its commercial portfolio after the United States Food and Drug Administration approved Pasatru, or garetosmab-grts, for adults with fibrodysplasia ossificans progressiva. The approval covers reduction of new heterotopic ossification lesions and clinician-assessed flare-ups, supported by Phase 3 OPTIMA results showing a 90% reduction in new lesions with the recommended 10 mg/kg starting dose compared with placebo at 56 weeks. For a company that generated approximately $4.3 billion of second-quarter revenue, Pasatru is unlikely to become a major revenue driver immediately because only about 900 people worldwide have been diagnosed with the ultra-rare disease. Its strategic importance could be considerably greater, however, because the approval validates decades of Regeneron Pharmaceuticals research into Activin A and establishes a new rare-disease franchise that could expand into younger patients and additional international markets.

The commercial equation is therefore different from blockbuster medicines such as Dupixent, EYLEA HD or Libtayo. Pasatru addresses an extremely small population, requires intravenous administration every four weeks and enters a United States market where Ipsen already sells Sohonos, the first FDA-approved FOP medicine. Regeneron Pharmaceuticals is nevertheless differentiated by mechanism, its Phase 3 flare-up data and the possibility of home infusion, while a European regulatory application remains under review in a market where Sohonos failed to obtain authorization.

Pasatru gives Regeneron a differentiated FOP franchise even if the addressable market remains tiny

Fibrodysplasia ossificans progressiva is caused by disease-driving alterations in the ACVR1 pathway and leads to progressive formation of bone within muscles, tendons, ligaments and other connective tissues. Abnormal bone can progressively restrict movement around the jaw, spine, hips and rib cage, interfering with activities including eating, walking and breathing. Regeneron Pharmaceuticals estimates that roughly 900 people are diagnosed worldwide, while many patients eventually become dependent on wheelchairs.

That extremely small population places a natural ceiling on Pasatru’s potential commercial scale, particularly compared with the enormous patient populations addressed by Regeneron Pharmaceuticals’ ophthalmology, immunology and oncology franchises. The company reported second-quarter 2026 revenue of $4.3 billion, up 17% year over year, while global Dupixent sales recorded by Sanofi reached $6 billion, EYLEA HD United States sales increased 52% to $596 million and global Libtayo sales rose 30% to $489 million.

Pasatru therefore does not need to become a multibillion-dollar medicine to make strategic sense. Its value can also come from expanding Regeneron Pharmaceuticals’ expertise in rare diseases, validating proprietary antibody technology and creating another internally discovered commercial asset alongside products such as Evkeeza and Veopoz. Regeneron Pharmaceuticals developed garetosmab using its VelocImmune platform after its scientists identified Activin A as an important biological driver of heterotopic ossification in FOP.

Pasatru is a fully human monoclonal antibody designed to neutralize Activin A before the protein can contribute to abnormal ACVR1 signaling and subsequent bone formation. That mechanism differs fundamentally from Ipsen’s Sohonos, or palovarotene, which is a retinoid and became the first FDA-approved treatment for FOP in August 2023. Sohonos is approved to reduce the volume of new heterotopic ossification in adults and in females aged eight years and older and males aged 10 years and older.

The two products also offer very different treatment formats. Sohonos is taken orally, while Pasatru begins with a 10 mg/kg intravenous infusion lasting approximately 60 minutes every four weeks, with the dose capable of being reduced to 3 mg/kg if the starting regimen is not tolerated. Regeneron Pharmaceuticals said Pasatru can be administered in multiple care environments, including through home infusion where appropriate, potentially reducing some of the logistical disadvantage associated with monthly intravenous treatment.

The 90% lesion reduction is compelling, but OPTIMA shows why the approved 10 mg/kg dose matters

The Phase 3 OPTIMA study randomized 63 adults with genetically confirmed FOP and evidence of disease activity or progression to Pasatru 10 mg/kg, Pasatru 3 mg/kg or placebo every four weeks. Whole-body computed tomography imaging was used to identify new heterotopic ossification lesions through 56 weeks, while clinician and patient assessments measured flare-up activity.

Only two new lesions developed among 23 participants receiving the 10 mg/kg dose compared with 19 lesions among 21 placebo recipients, representing a 90% reduction. The 3 mg/kg group recorded only one new lesion among 19 participants, producing a 94% reduction and allowing both Pasatru dose groups to meet the primary efficacy endpoint.

The secondary flare-up findings make the dose selection more interesting. Clinicians reported only nine flare-ups among participants receiving Pasatru 10 mg/kg compared with 66 in the placebo group, an 88% reduction. The 3 mg/kg group experienced 53 flare-ups, only 15% fewer than placebo, while patient-reported flare-up proportions were not significantly different between treatment groups.

Those results explain why the apparently similar lesion reductions should not be interpreted as evidence that the lower dose performs equally across every clinically relevant measure. The recommended starting regimen is 10 mg/kg, with the 3 mg/kg dose functioning as an option when the higher dose is not tolerated. The distinction will matter as physicians gain real-world experience and determine whether patients can remain on the higher regimen over prolonged treatment.

The safety profile will also influence adoption. Common adverse reactions reported in at least 10% of Pasatru-treated adults included abscesses, acne, increased hair growth, loss of eyebrows or eyelashes, oral ulcers, nosebleeds, folliculitis, nail infections and rash. Serious treatment-emergent adverse events occurred in two patients receiving 10 mg/kg, one receiving 3 mg/kg and two receiving placebo.

Regeneron Pharmaceuticals also warns about embryo-fetal toxicity, skin and soft-tissue infections and potentially serious nosebleeds. The company will therefore need to show that the substantial suppression of new abnormal bone formation translates into an acceptable long-term benefit-risk profile when treatment expands beyond the controlled Phase 3 environment.

European review and pediatric development could determine how far Pasatru grows beyond its initial label

The United States approval currently covers only adults, leaving younger patients outside the Pasatru label despite FOP beginning much earlier in life. Regeneron Pharmaceuticals plans to address that limitation through OPTIMA 2, a Phase 3 study in children and adolescents expected to begin later in 2026.

Pediatric expansion could substantially improve the long-term clinical relevance of the franchise because FOP causes cumulative and irreversible heterotopic ossification. Preventing new lesions earlier in the disease course could theoretically have considerable value, although that possibility must be demonstrated prospectively rather than inferred from the adult OPTIMA result. Regeneron Pharmaceuticals has stated that safety and efficacy of Pasatru have not yet been established in children.

International expansion provides another meaningful opportunity. The European Medicines Agency is reviewing the Pasatru application, while Regeneron Pharmaceuticals plans additional submissions including in Japan. That European decision could be particularly important because Ipsen’s palovarotene failed to obtain European Union authorization after the European Commission followed a negative regulatory opinion in 2023.

A European approval could therefore give Pasatru a comparatively stronger competitive position than it has in the United States, where Sohonos has been available since 2023. Whether that translates into meaningful commercial scale will still depend on diagnosis rates, reimbursement, infusion infrastructure and adoption within an exceptionally small global patient population.

The commercial opportunity may consequently be less about taking a large percentage of Regeneron Pharmaceuticals’ total revenue and more about building a defensible high-value rare-disease franchise. Ultra-rare medicines can support meaningful economics even with small patient populations, but pricing, reimbursement and patient access will determine whether Pasatru produces an attractive return on the lengthy scientific investment behind the program. Regeneron Pharmaceuticals had not disclosed a Pasatru sales forecast in its approval announcement.

REGN shares rise nearly 4% as Pasatru adds another approval to a fast-growing commercial portfolio

Regeneron Pharmaceuticals shares finished August 19 at approximately $840.84, up $30.96 or about 3.8% from the previous close after trading as high as $844.73. The company’s market capitalization stood near $89.1 billion.

The positive session coincided with the Pasatru approval, but assigning the entire move to one ultra-rare disease product would overstate its likely financial significance. Regeneron Pharmaceuticals is a diversified biotechnology company with nearly $90 billion of market capitalization and multiple large commercial franchises, so daily trading reflects broader expectations around earnings, pipeline developments and the biotechnology sector. The approval is nevertheless incrementally positive because it removes the regulatory risk surrounding another late-stage asset and converts garetosmab from research and development spending into a commercial product.

The broader financial backdrop is supportive. Regeneron Pharmaceuticals reported 17% second-quarter revenue growth to approximately $4.3 billion, while several key growth franchises reached record sales levels. Dupixent global sales increased 38% to about $6 billion, EYLEA HD United States sales rose 52% and Libtayo global sales increased 30%.

That scale gives Regeneron Pharmaceuticals the flexibility to pursue ultra-rare diseases without requiring every approved medicine to become a blockbuster. Pasatru can be commercially modest while still creating value through premium rare-disease economics, scientific validation and expansion opportunities in pediatric and international markets.

The approval also strengthens a recurring theme across Regeneron Pharmaceuticals’ portfolio: internally discovered biology being translated through the company’s proprietary antibody technology into marketed medicines. Activin A was identified by Regeneron Pharmaceuticals researchers as a central driver of heterotopic ossification in FOP, and Pasatru now converts that biological insight into an FDA-approved product.

The next phase is less about regulatory possibility and more about commercial execution. Regeneron Pharmaceuticals must establish reimbursement, infusion access and physician adoption while pursuing European approval and pediatric development. For a disease affecting only hundreds of diagnosed patients worldwide, each treatment decision matters disproportionately, making Pasatru a very different commercial challenge from Dupixent or EYLEA HD.

Key takeaways on what Pasatru FDA approval means for Regeneron Pharmaceuticals

• The FDA approved Pasatru for reducing new heterotopic ossification lesions and clinician-assessed flare-ups in adults with fibrodysplasia ossificans progressiva.
• The approved 10 mg/kg starting dose produced a 90% reduction in new lesions versus placebo during the 56-week Phase 3 OPTIMA trial.
• Clinician-assessed flare-ups fell 88% with the 10 mg/kg regimen, while the lower 3 mg/kg dose produced only a 15% reduction on that secondary measure.
• Pasatru is administered intravenously every four weeks and can potentially be delivered through home infusion when appropriate.
• Ipsen’s Sohonos remains an established United States competitor and was the first FDA-approved FOP treatment in 2023.
• Pasatru uses an Activin A-blocking mechanism that differs from the retinoid mechanism used by Sohonos.
• Regeneron Pharmaceuticals plans a pediatric Phase 3 study later in 2026, creating a potential path beyond the current adult-only indication.
• The European Medicines Agency is reviewing Pasatru, potentially giving Regeneron Pharmaceuticals an opportunity in a market where Sohonos did not receive European Union authorization.
• Regeneron Pharmaceuticals generated about $4.3 billion of second-quarter revenue, making Pasatru strategically important but unlikely to materially alter near-term companywide sales by itself.
• REGN finished August 19 around $840.84, up approximately 3.8%, with a market capitalization of about $89.1 billion.